上海仁度生物科技股份有限公司2025年半年度报告摘要

Core Viewpoint - Shanghai Rendu Biotech Co., Ltd. has obtained IVDR CE certification for three nucleic acid testing products, enabling entry into the EU market and enhancing competitiveness in the in vitro diagnostic product sector [12]. Group 1: Company Overview - The company is identified as Shanghai Rendu Biotech Co., Ltd. with stock code 688193 [12]. - The company held its second supervisory board meeting on August 28, 2025, with full attendance [7]. Group 2: Financial Data - The company raised a total of RMB 726.5 million through its initial public offering, with a net amount of RMB 652.76 million after deducting issuance costs [24][25]. - As of the end of the reporting period, the company had utilized RMB 283.99 million of the raised funds, with RMB 31.16 million used in the first half of 2025 [26]. Group 3: Significant Events - The company plans to participate in a collective performance briefing for the medical device industry on September 17, 2025, to discuss its 2025 semi-annual results [16][18]. - The supervisory board approved the semi-annual report and the special report on the use of raised funds, confirming compliance with relevant regulations [10][44]. Group 4: Regulatory Compliance - The company has established a management system for the storage and use of raised funds, ensuring compliance with regulatory requirements [26]. - The company has not engaged in any violations regarding the use of raised funds, maintaining transparency and adherence to regulations [38].